Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer

被引:6
作者
Liang, Yan [1 ,2 ]
Zhang, Purong [1 ]
Li, Feng [1 ,2 ]
Lai, Houyun [1 ,2 ]
Qi, Tingting [1 ]
Wang, Yixin [1 ]
机构
[1] Univ Elect Sci & Technol, Sichuan Canc Hosp, Canc Hosp, Chengdu, Peoples R China
[2] Univ Elect Sci & Technol, Sch Med, Chengdu, Peoples R China
关键词
breast cancer; T-DM1; T-DXd; SG; ADC; GROWTH-FACTOR RECEPTOR; TRASTUZUMAB EMTANSINE T-DM1; PHASE-III ASCENT; SACITUZUMAB GOVITECAN; OPEN-LABEL; PHYSICIANS CHOICE; SINGLE-ARM; DERUXTECAN; SURVIVAL; RESISTANCE;
D O I
10.3389/fphar.2023.1332539
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Breast cancer continues to have a high incidence rate among female malignancies. Despite significant advancements in treatment modalities, the heterogeneous nature of breast cancer and its resistance to various therapeutic approaches pose considerable challenges. Antibody-drug conjugates (ADCs) effectively merge the specificity of antibodies with the cytotoxicity of chemotherapeutic agents, offering a novel strategy for precision treatment of breast cancer. Notably, trastuzumab emtansine (T-DM1) has provided a new therapeutic option for HER2-positive breast cancer patients globally, especially those resistant to conventional treatments. The development of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) has further broadened the applicability of ADCs in breast cancer therapy, presenting new hopes for patients with low HER2 expression and triple-negative breast cancer. However, the application of ADCs presents certain challenges. For instance, their treatment may lead to adverse reactions such as interstitial lung disease, thrombocytopenia, and diarrhea. Moreover, prolonged treatment could result in ADCs resistance, complicating the therapeutic process. Economically, the high costs of ADCs might hinder their accessibility in low-income regions. This article reviews the structure, mechanism of action, and clinical trials of commercially available ADCs for breast cancer treatment, with a focus on the clinical trials of the three drugs, aiming to provide insights for clinical applications and future research.
引用
收藏
页数:26
相关论文
共 148 条
[1]   Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 [J].
Abraham, Jame ;
Montero, Albert J. ;
Jankowitz, Rachel C. ;
Salkeni, Mohamad Adham ;
Beumer, Jan H. ;
Kiesel, Brian F. ;
Piette, Fanny ;
Adamson, Laura M. ;
Nagy, Rebecca J. ;
Lanman, Richard B. ;
Sperinde, Jeff ;
Huang, Weidong ;
Allegra, Carmen J. ;
Srinivasan, Ashok ;
Wang, Ying ;
Pogue-Geile, Katherine L. ;
Lucas, Peter C. ;
Jacobs, Samuel A. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (29) :2601-+
[2]   Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review [J].
Abuhelwa, Ziad ;
Alloghbi, Abdurahman ;
Alqahtani, Ali ;
Nagasaka, Misako .
DRUGS, 2022, 82 (09) :979-987
[3]   Trop-2 Is a Determinant of Breast Cancer Survival [J].
Ambrogi, Federico ;
Fornili, Marco ;
Boracchi, Patrizia ;
Trerotola, Marco ;
Relli, Valeria ;
Simeone, Pasquale ;
La Sorda, Rossana ;
Lattanzio, Rossano ;
Querzoli, Patrizia ;
Pedriali, Massimo ;
Piantelli, Mauro ;
Biganzoli, Elia ;
Alberti, Saverio .
PLOS ONE, 2014, 9 (05)
[4]   Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, 3 trial [J].
Andre, Fabrice ;
Park, Yeon Hee ;
Kim, Sung-Bae ;
Takano, Toshimi ;
Im, Seock-Ah ;
Borges, Giuliano ;
Lima, Joao Paulo ;
Aksoy, Sercan ;
Gavila Gregori, Joaquin ;
De Laurentiis, Michelino ;
Bianchini, Giampaolo ;
Roylance, Rebecca ;
Miyoshi, Yasuo ;
Armstrong, Anne ;
Sinha, Rajni ;
Ruiz Borrego, Manuel ;
Lim, Elgene ;
Ettl, Johannes ;
Yerushalmi, Rinat ;
Zagouri, Flora ;
Duhoux, Francois P. ;
Fehm, Tanja ;
Gambhire, Dhiraj ;
Cathcart, Jillian ;
Wu, Cai ;
Chu, Changan ;
Egorov, Anton ;
Krop, Ian .
LANCET, 2023, 401 (10390) :1773-1785
[5]   Oncogene-mediated metabolic gene signature predicts breast cancer outcome [J].
Aslan, Merve ;
Hsu, En-Chi ;
Garcia-Marques, Fernando J. ;
Bermudez, Abel ;
Liu, Shiqin ;
Shen, Michelle ;
West, Meredith ;
Zhang, Chiyuan Amy ;
Rice, Meghan A. ;
Brooks, James D. ;
West, Robert ;
Pitteri, Sharon J. ;
Gyorffy, Balazs ;
Stoyanova, Tanya .
NPJ BREAST CANCER, 2021, 7 (01)
[6]   Irinotecan: 25 years of cancer treatment [J].
Bailly, Christian .
PHARMACOLOGICAL RESEARCH, 2019, 148
[7]   Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer [J].
Bardia, A. ;
Tolaney, S. M. ;
Punie, K. ;
Loirat, D. ;
Oliveira, M. ;
Kalinsky, K. ;
Zelnak, A. ;
Aftimos, P. ;
Dalenc, F. ;
Sardesai, S. ;
Hamilton, E. ;
Sharma, P. ;
Recalde, S. ;
Gil, E. C. ;
Traina, T. ;
O'Shaughnessy, J. ;
Cortes, J. ;
Tsai, M. ;
Vahdat, L. ;
Dieras, V ;
Carey, L. A. ;
Rugo, H. S. ;
Goldenberg, D. M. ;
Hong, Q. ;
Olivo, M. ;
Itri, L. M. ;
Hurvitz, S. A. .
ANNALS OF ONCOLOGY, 2021, 32 (09) :1148-1156
[8]   Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial [J].
Bardia, A. ;
Messersmith, W. A. ;
Kio, E. A. ;
Berlin, J. D. ;
Vahdat, L. ;
Masters, G. A. ;
Moroose, R. ;
Santin, A. D. ;
Kalinsky, K. ;
Picozzi, V ;
O'Shaughnessy, J. ;
Gray, J. E. ;
Komiya, T. ;
Lang, J. M. ;
Chang, J. C. ;
Starodub, A. ;
Goldenberg, D. M. ;
Sharkey, R. M. ;
Maliakal, P. ;
Hong, Q. ;
Wegener, W. A. ;
Goswami, T. ;
Ocean, A. J. .
ANNALS OF ONCOLOGY, 2021, 32 (06) :746-756
[9]   Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].
Bardia, A. ;
Hurvitz, S. A. ;
Tolaney, S. M. ;
Loirat, D. ;
Punie, K. ;
Oliveira, M. ;
Brufsky, A. ;
Sardesai, S. D. ;
Kalinsky, K. ;
Zelnak, A. B. ;
Weaver, R. ;
Traina, T. ;
Dalenc, F. ;
Aftimos, P. ;
Lynce, F. ;
Diab, S. ;
Cortes, J. ;
O'Shaughnessy, J. ;
Dieras, V ;
Ferrario, C. ;
Schmid, P. ;
Carey, L. A. ;
Gianni, L. ;
Piccart, M. J. ;
Loibl, S. ;
Goldenberg, D. M. ;
Hong, Q. ;
Olivo, M. S. ;
Itri, L. M. ;
Rugo, H. S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541
[10]   Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer [J].
Bardia, A. ;
Mayer, I. A. ;
Vahdat, L. T. ;
Tolaney, S. M. ;
Isakoff, S. J. ;
Diamond, J. R. ;
O'Shaughnessy, J. ;
Moroose, R. L. ;
Santin, A. D. ;
Abramson, V. G. ;
Shah, N. C. ;
Rugo, H. S. ;
Goldenberg, D. M. ;
Sweidan, A. M. ;
Iannone, R. ;
Washkowitz, S. ;
Sharkey, R. M. ;
Wegener, W. A. ;
Kalinsky, K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08) :741-751